Hemostemix Annonces it is Trading on the Frankfurt
Stock Exchange
and it has Retained HE Capital Markets
LTD.
Calgary,
Alberta, April
8, 2021 --
InvestorsHub NewsWire -- Hemostemix
Inc.
("Hemostemix"
or the "Company")
(TSXV:HEM,
OTC: HMTXF, Frankfurt: 2VFO.F) is pleased to
announce it is trading on the Frankfurt Stock Exchange under symbol
2VFO.F and it has engaged HE
Capital Markets Ltd. (HE Capital)
to design
and implement a North American and European multimedia digital
advertising campaign on certain investor-focused and financial
market websites. HE Capital will also provide other media
communications services to raise the company's overall corporate
profile in North America and Europe.
Thomas
Smeenk,
CEO, said: "With the listing on Frankfurt and the engagement of
HE Capital, we are
deepening our liquidity pools, introducing Hemostemix
to a
broader investment community. In the USA we are working to up-list
the company, and
we
are
exploring
how
best to reach our
audience in
Asia,"
Smeenk
said.
The cash
consideration to be paid by the company for these services consists
of USD
$18,000
for
an
initial three-month
campaign. HE Capital acts at
arm's length to Hemostemix
and does
not currently have any interest, directly or indirectly, in the
company or its securities. HE Capital may choose to acquire
securities of Hemostemix
in the
future.
HE Capital is a
London-based investor relation and capital markets advisory firm,
providing comprehensive communications solutions to public company
clients in North America and Europe through a combination of
investor relations, public relations, and digital and social media
services. HE Capital's office address is 6 Hays Lane, London
Bridge, London, SE1 2HB, United Kingdom.
About
Hemostemix
Hemostemix
is a
publicly traded autologous stem cell therapy
company. A winner of the
World Economic Forum Technology Pioneer Award, the Company
developed and is commercializing its lead product ACP-01 for the
treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated
Cardiomyopathy and other conditions of ischemia.
ACP-01 has been used to
treat over 300 patients, and it
is the subject of a randomized, placebo-controlled, double blind
trial of its safety and efficacy in patients with advanced critical
limb ischemia who have exhausted all other options to save their
limb from amputation.
On October 21, 2019, the Company announced
the results from its
Phase II multi-center randomized double-blind placebo-controlled
clinical trial of ACP-01 in critical limb ischemia (CLI)
abstract
entitled
"Autologous Stem Cell Treatment for CLI Patients with No
Revascularization Options: An Update of the Hemostemix
ACP-01
Trial With 4.5 Year Followup"
which noted healing of ulcers and resolution of ischemic rest pain
occurred in 83% of patients, with outcomes maintained for up to 4.5
years.
The
Company owns 91 patents across five patent families titled:
Regulating Stem Cells, In Vitro Techniques for use with Stem Cells,
Production from Blood of Cells of Neural Lineage, and Automated
Cell Therapy. For more information, please visit
www.hemostemix.com.
Contact:
Thomas
Smeenk,
President, CEO & Co-Founder
TSmeenk@Hemostemix.com
905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service
Provider (as that term is defined under the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-Looking Information: This
news release contains "forward-looking information" within the
meaning of applicable Canadian securities legislation. All
statements, other than statements of historical fact, included
herein are forward-looking information. In
particular, this news
release contains
forward-looking information regarding the financing of
Hemostemix,
settlement of trade accounts payable with shares.
There
can be no assurance that such forward-looking information will
prove to be accurate.
Actual
results and future events could differ materially from those
anticipated in such forward-looking information. This
forward-looking information reflects Hemostemix's
current
beliefs and is based on information currently available to
Hemostemix
and
on assumptions Hemostemix
believes
are reasonable. These
assumptions include, but are not limited to: the underlying value
of Hemostemix
and
its common shares; the successful resolution of the litigation
that Hemostemix
is
pursuing or defending (the "Litigation");
the timing of receipt of its full and complete clinical trials
data; the results of ACP-01 research, trials and studies being
equivalent to or better than previous research, trials or studies
as well as management's expectations
of anticipated results; Hemostemix's
general
and administrative costs remaining constant; the receipt of all
required regulatory approvals
for research, trials or studies as well as the
disclosed or any
required or desired financings of Hemostemix,
including TSX Venture Exchange acceptance and
any third party consents; the level of activity, market acceptance
and market trends in the healthcare sector; the economy
generally; consumer interest
in Hemostemix's
services
and products; competition and Hemostemix's
competitive
advantages; and,a
obtaining
satisfactory financing to fund
Hemostemix's
operations
including any research, trials or studies, and the
Litigation. Forward-looking
information is subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, level of
activity, performance or achievements of Hemostemix
to
be materially different from those expressed or implied by such
forward-looking information. Such risks and other factors may
include, but are not limited to: the ability of Hemostemix
to
complete its current CLI clinical trial, complete a satisfactory
futility analysis and the results of such and future clinical
trials; litigation
and potential litigation that Hemostemix
may
face; general business, economic, competitive, political and social
uncertainties; general capital market conditions and market prices
for securities; delay or failure to receive board or regulatory
approvals; the
actual results of future operations including
the actual results of future research, trials or
studies; competition;
changes in legislation affecting
Hemostemix;
the timing and availability of external financing on acceptable
terms; long-term capital requirements and future developments
in Hemostemix's
markets
and the markets in which it expects to compete; lack
of qualified, skilled labour
or
loss of key individuals; and risks related
to the COVID-19 pandemic including various recommendations, orders
and measures of governmental authorities to try
to limit the pandemic, including travel restrictions, border
closures, non-essential business closures, service
disruptions,
quarantines,
self-isolations, shelters-in-place and social distancing,
disruptions to markets, disruptions
to economic
activity
and financings,
disruptions
to supply
chains and sales channels, and a deterioration of general economic
conditions including a possible
national or global recession or
depression; the
potential impact that the COVID-19 pandemic may have on
Hemostemix
may
include a decreased demand for the services that Hemostemix
offers;
and a deterioration of financial markets that could limit
Hemostemix's
ability
to obtain external financing. A description of additional risk
factors that may cause actual results to differ materially from
forward-looking information can be found in Hemostemix's
disclosure
documents on the SEDAR website at www.sedar.com. Although
Hemostemix
has
attempted to identify important factors that could cause actual
results to differ materially from those contained in
forward-looking information, there may be other factors that cause
results not to be as anticipated, estimated or
intended. Readers
are cautioned that the foregoing list of factors is not
exhaustive. Readers
are further cautioned not to place undue reliance on
forward-looking information as there can be no assurance that the
plans, intentions or expectations upon which they are placed will
occur. Forward-looking information contained in this news release
is expressly qualified by this cautionary statement. The
forward-looking information contained in this news release
represents the expectations of Hemostemix
as
of the date of this news release and, accordingly, it
is
subject to change after such date. However,
Hemostemix
expressly
disclaims any intention or obligation to update or revise any
forward-looking information, whether as a result of new
information,
future events or otherwise, except as expressly required by
applicable securities law.
Hemostemix (PK) (USOTC:HMTXF)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Hemostemix (PK) (USOTC:HMTXF)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024